Kala Pharmaceuticals Inc
$ 0.38
0.16%
23 Feb - close price
- Market Cap 346,305,000 USD
- Current Price $ 0.38
- High / Low $ 0.42 / 0.38
- Stock P/E N/A
- Book Value -1.17
- EPS -5.64
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.66 %
- ROE -7.08 %
- 52 Week High 20.60
- 52 Week Low 0.35
About
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$1.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-19 | 2025-08-08 | 2025-05-12 | 2025-03-27 | 2024-11-11 | 2024-08-06 | 2024-05-14 | 2024-03-29 | 2023-11-13 | 2023-08-04 | 2023-05-09 | 2023-03-03 |
| Reported EPS | -1.07 | -1.71 | -1.7414 | -1.2316 | -1.9341 | -3.16 | -4.19 | -3.18 | -3.41 | -4.36 | -6.99 | -7.97 |
| Estimated EPS | -2.81 | -2.93 | -2.54 | -2.47 | -2.43 | -4.4 | -2.89 | -3.62 | -2.15 | -3.19 | -4.52 | -6.55 |
| Surprise | 1.74 | 1.22 | 0.7986 | 1.2384 | 0.4959 | 1.24 | -1.3 | 0.44 | -1.26 | -1.17 | -2.47 | -1.42 |
| Surprise Percentage | 61.9217% | 41.6382% | 31.4409% | 50.1377% | 20.4074% | 28.1818% | -44.9827% | 12.1547% | -58.6047% | -36.6771% | -54.646% | -21.6794% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KALA
2026-01-06 08:16:07
Kala Pharmaceuticals Inc. stock surged 14% after successfully settling its $10.6 million debt obligations with Oxford Finance for a $2 million payment. This resolution eliminates a significant financial overhang, strengthening the company's balance sheet and increasing strategic flexibility. The company also approved common stock awards for new employees.
2026-01-05 21:09:18
Kala Pharmaceuticals Inc. (NASDAQ:KALA) saw its stock surge 14% after announcing it settled its debt obligations with Oxford Finance, LLC. The company made a $2 million payment, discharging approximately $10.6 million in debt, which is expected to remove a "substantial overhang" and strengthen its balance sheet. Additionally, Kala disclosed common stock awards totaling 400,000 shares to four new employees.
2025-12-14 10:09:30
KALA BIO, Inc. (NASDAQ: KALA) shares surged over 22% in after-hours trading following news that Oxford Finance LLC acquired a 16.5% ownership stake in the company. This ownership is based on 9.82 million total shares, including 8.20 million outstanding shares and the 1.62 million shares issued to Oxford Finance. Additionally, last week investor David Lazar was named Chief Executive Officer, contributing to investor interest.
2025-12-06 12:09:53
KALA BIO, Inc. announced the closing of a registered direct offering of 10,000,000 shares of its common stock (or pre-funded warrants) at $1.00 per share, raising approximately $10 million in gross proceeds. The company intends to use the net proceeds to repay debt and for general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
2025-12-06 04:32:01
Kala Pharmaceuticals Inc. (NASDAQ:KALA) saw its stock drop 6.7% after closing a registered direct offering that raised approximately $10 million. The company sold 10 million shares or pre-funded warrants at $1.00 per share, with H.C. Wainwright & Co. acting as the exclusive placement agent. Kala intends to use the net proceeds to repay outstanding debt and for general corporate purposes, but the offering led to existing shareholder dilution and a decline in stock value.
2025-12-05 14:36:00
KALA BIO, Inc. announced the closing of a $10 million registered direct offering of common stock, priced at-the-market under Nasdaq rules. The company sold 10,000,000 shares (or pre-funded warrants) at $1.00 each. The proceeds are intended for debt repayment and general corporate purposes.
